tecfidera

Biogen fends off Mylan’s challenge to patent on top-selling multiple sclerosis drug

The Patent Trial and Appeal Board ruled against the generic drugmaker's inter partes review seeking to overturn the patent covering Tecfidera. The drug, which had $4.4 billion in sales last year, could remain protected through February 2028.

By Alaric DeArment

BioPharma

Biogen, Alkermes MS drug bests Biogen’s soon-to-be-generic blockbuster in Phase III study

An analyst wrote that while the new drug, Vumerity, has a good chance of winning FDA approval later this year, it is uncertain whether the superior gastrointestinal tolerability it demonstrated will be enough to protect Tecfidera from generic competition.

By Alaric DeArment